[go: up one dir, main page]

MA29216B1 - Composes et compositions utilises comme inhibiteurs de la proteine kinase - Google Patents

Composes et compositions utilises comme inhibiteurs de la proteine kinase

Info

Publication number
MA29216B1
MA29216B1 MA29953A MA29953A MA29216B1 MA 29216 B1 MA29216 B1 MA 29216B1 MA 29953 A MA29953 A MA 29953A MA 29953 A MA29953 A MA 29953A MA 29216 B1 MA29216 B1 MA 29216B1
Authority
MA
Morocco
Prior art keywords
compounds
compositions
inhibitors
protein kinase
disorders
Prior art date
Application number
MA29953A
Other languages
English (en)
Inventor
Yongqin Wan
Yuan Mi
Yi Fan
Dai Cheng
Yi Liu
Nathanael Schiander Gray
Pamela A Albaugh
Original Assignee
Irm Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Irm Llc filed Critical Irm Llc
Publication of MA29216B1 publication Critical patent/MA29216B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pregnancy & Childbirth (AREA)
  • Dermatology (AREA)
  • Virology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)

Abstract

L'INVENTION CONCERNE UNE NOUVELLE CLASSE DE COMPOSÉS, DES COMPOSITIONS RENFERMANT CES COMPOSÉS ET DES MÉTHODES D'UTILISATION DESDITS COMPOSÉS POUR LE TRAITEMENT OU LA PRÉVENTION DE MALADIES OU DE TROUBLES ASSOCIÉS À UNE ACTIVITÉ ANORMALE OU SAUVAGE DE KINASES, EN PARTICULIER DES MALADIES ET DES TROUBLES EN RAPPORT AVEC UNE ACTIVATION ANORMALE DES KINASES ABL, BCR-ABL, CSRC, TPR-MET, TIE2, MET, FGFR3, AURORA, AXL, BMX, BTK, C-KIT, CHK2, FLT3, MST2, P70S6K, PDGFR, PKB, PKC, RAF, ROCK-II, RSK1, SGK, TRKA, TRKB ET TRKC.
MA29953A 2004-11-09 2007-05-30 Composes et compositions utilises comme inhibiteurs de la proteine kinase MA29216B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62678504P 2004-11-09 2004-11-09
US70964805P 2005-08-19 2005-08-19

Publications (1)

Publication Number Publication Date
MA29216B1 true MA29216B1 (fr) 2008-02-01

Family

ID=36337126

Family Applications (1)

Application Number Title Priority Date Filing Date
MA29953A MA29216B1 (fr) 2004-11-09 2007-05-30 Composes et compositions utilises comme inhibiteurs de la proteine kinase

Country Status (17)

Country Link
US (1) US8101608B2 (fr)
EP (1) EP1814545A4 (fr)
JP (1) JP4917041B2 (fr)
KR (1) KR20070084066A (fr)
AR (1) AR053652A1 (fr)
AU (1) AU2005304719B2 (fr)
BR (1) BRPI0517968A (fr)
CA (1) CA2583737C (fr)
GT (1) GT200500321A (fr)
IL (1) IL182687A0 (fr)
MA (1) MA29216B1 (fr)
MX (1) MX2007005547A (fr)
NO (1) NO20072887L (fr)
RU (1) RU2406725C2 (fr)
TN (1) TNSN07176A1 (fr)
TW (1) TW200631577A (fr)
WO (1) WO2006052936A2 (fr)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005118551A2 (fr) 2004-05-28 2005-12-15 Ligand Pharmaceuticals Inc. Composes modulant l'activite de la thrombopoietine et methodes associees
AU2005299720B2 (en) 2004-10-25 2010-02-04 Ligand Pharmaceuticals Incorporated Thrombopoietin activity modulating compounds and methods
EP1902025A1 (fr) 2005-07-13 2008-03-26 Allergan, Inc. Inhibiteurs de kinase
US7439371B2 (en) * 2005-07-13 2008-10-21 Allergan, Inc. Indol kinase inhibitors
US7749530B2 (en) 2005-07-13 2010-07-06 Allergan, Inc. Kinase inhibitors
UA93548C2 (uk) 2006-05-05 2011-02-25 Айерем Елелсі Сполуки та композиції як модулятори хеджхогівського сигнального шляху
DE102006024834B4 (de) * 2006-05-24 2010-07-01 Schebo Biotech Ag Neue Indol-Pyrrol-Derivate und deren Verwendungen
US8034957B2 (en) 2006-08-11 2011-10-11 Allergan, Inc. Kinase inhibitors
JP2010502741A (ja) * 2006-09-11 2010-01-28 キュリス，インコーポレイテッド Ｐｔｋインヒビターとしての亜鉛結合部分を含む置換２−インドリノン
WO2008033562A2 (fr) 2006-09-15 2008-03-20 Xcovery, Inc. Composés inhibiteurs de kinases
CN101522026A (zh) * 2006-10-06 2009-09-02 Irm责任有限公司 蛋白激酶抑制剂及其应用方法
NZ579480A (en) 2007-03-14 2012-03-30 Exelixis Patent Co Llc 2-Arylamino-quinazoline derivatives
EP2217716A4 (fr) 2007-11-09 2011-02-09 Salk Inst For Biological Studi Utilisation d'inhibiteurs de récepteurs tam en tant qu'antimicrobiens
CN102083828B (zh) * 2008-02-22 2013-11-13 Irm责任有限公司 作为c-kit和pdgfr激酶抑制剂的杂环化合物和组合物
JP5305704B2 (ja) * 2008-03-24 2013-10-02 富士フイルム株式会社 新規化合物、光重合性組成物、カラーフィルタ用光重合性組成物、カラーフィルタ、及びその製造方法、固体撮像素子、並びに、平版印刷版原版
CA2722606A1 (fr) * 2008-05-05 2009-11-12 Amgen Inc. Composes d'uree acycliques servant de modulateurs de la gamma-secretase
EP2273882A4 (fr) * 2008-05-13 2011-07-13 Poniard Pharmaceuticals Inc Composés bioactifs pour le traitement du cancer et des maladies neurodégénératives
EA029131B1 (ru) 2008-05-21 2018-02-28 Ариад Фармасьютикалз, Инк. Фосфорсодержащие производные в качестве ингибиторов киназы
US9273077B2 (en) 2008-05-21 2016-03-01 Ariad Pharmaceuticals, Inc. Phosphorus derivatives as kinase inhibitors
EP2671891A3 (fr) 2008-06-27 2014-03-05 Amgen Inc. Inhibition d'ang-2 pour traiter la sclérose en plaques
CN102115472B (zh) * 2010-01-04 2013-12-04 深圳市天和医药科技开发有限公司 3-(2-吡咯亚甲基)氮杂吲哚啉-2-酮衍生物及其制法与应用
GB201014374D0 (en) * 2010-08-27 2010-10-13 Univ Greenwich Novel hybrid compounds
CA2832504C (fr) 2011-05-04 2019-10-01 Ariad Pharmaceuticals, Inc. Composes permettant d'inhiber la proliferation cellulaire dans les cancers induits par l'egfr
RU2642463C2 (ru) 2012-04-20 2018-01-25 Аннцзи Фармасьютикал Ко., Лтд. Циклопропанкарбоксилатные эфиры пуриновых аналогов
AU2013204563B2 (en) 2012-05-05 2016-05-19 Takeda Pharmaceutical Company Limited Compounds for inhibiting cell proliferation in EGFR-driven cancers
WO2014018535A1 (fr) 2012-07-25 2014-01-30 Salk Institute For Biological Studies Régulation de l'interaction entre les ligands de tam et les membranes lipidiques contenant de la phosphatidylsérine
US9296730B2 (en) 2012-10-26 2016-03-29 Regents Of The University Of Minnesota Aurora kinase inhibitors
US9611283B1 (en) 2013-04-10 2017-04-04 Ariad Pharmaceuticals, Inc. Methods for inhibiting cell proliferation in ALK-driven cancers
WO2016161572A1 (fr) 2015-04-08 2016-10-13 Merck Sharp & Dohme Corp. Inhibiteurs de la kinase trka, compositions et procédés associés
US10487054B2 (en) 2017-04-21 2019-11-26 Regents Of The University Of Minnesota Therapeutic compounds
SG11202007198WA (en) 2018-01-31 2020-08-28 Deciphera Pharmaceuticals Llc Combination therapy for the treatment of gastrointestinal stromal tumors
CA3089630A1 (fr) 2018-01-31 2019-08-08 Deciphera Pharmaceuticals, Llc Polytherapie pour le traitement de la mastocytose
WO2020185812A1 (fr) 2019-03-11 2020-09-17 Teva Pharmaceuticals International Gmbh Formes à l'état solide de riprétinib
KR20220045189A (ko) 2019-08-12 2022-04-12 데시페라 파마슈티칼스, 엘엘씨. 위장관 기질 종양을 치료하는 방법
TWI878335B (zh) 2019-08-12 2025-04-01 美商迪賽孚爾製藥有限公司 治療胃腸道基質瘤方法
BR112022005595A2 (pt) 2019-09-27 2022-07-19 Takeda Pharmaceuticals Co Composto, medicamento, métodos para inibir histona deacetilase 6 e para profilaxia ou tratamento de doença de alzheimer ou paralisia supranuclear progressiva em um mamífero, e, uso de composto
SMT202300467T1 (it) 2019-12-30 2024-01-10 Deciphera Pharmaceuticals Llc Formulazioni di inibitori di chinasi amorfi e loro procedimenti d’uso
SMT202400484T1 (it) 2019-12-30 2025-01-14 Deciphera Pharmaceuticals Llc Composizioni di 1-(4-bromo-5-(1-etil-7-(metilammino)-2-osso-1,2-diidro-1,6-naftiridin-3-il)-2-fluorofenil)-3-fenilurea
CN114853735B (zh) * 2022-07-06 2022-10-21 北京鑫开元医药科技有限公司 靶向泛素化降解trk的化合物及其制备方法、组合物和用途
CN114853736B (zh) * 2022-07-06 2022-10-21 北京鑫开元医药科技有限公司 具有trk抑制活性的化合物、制备方法、组合物及其用途
US11779572B1 (en) 2022-09-02 2023-10-10 Deciphera Pharmaceuticals, Llc Methods of treating gastrointestinal stromal tumors
WO2024054793A1 (fr) 2022-09-09 2024-03-14 University Of Rochester Inhibition de l'efferocytose en tant que traitement pour prévenir la perte osseuse et augmenter la densité et la résistance osseuses
CN118221652B (zh) * 2022-12-19 2025-06-06 沈阳药科大学 一种吲哚-2-酮衍生物及其制备方法和用途

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5565483A (en) * 1995-06-07 1996-10-15 Bristol-Myers Squibb Company 3-substituted oxindole derivatives as potassium channel modulators
GB9718913D0 (en) * 1997-09-05 1997-11-12 Glaxo Group Ltd Substituted oxindole derivatives
EP1066257A2 (fr) * 1998-03-26 2001-01-10 Sugen, Inc. Familles heterocycliques de composes destinees a la modulation de la tyrosine-kinase
ES2211096T3 (es) * 1998-05-28 2004-07-01 Biogen, Inc. Un inhibidor de vla-4: omepupa-v.
HUP0103617A2 (hu) 1998-05-29 2002-02-28 Sugen, Inc. Protein kinázt gátló, pirrolilcsoporttal helyettesített 2-indolszármazékok, e vegyületeket tartalmazó gyógyászati készítmények, valamint e vegyületek alkalmazása
JP2002522452A (ja) * 1998-08-04 2002-07-23 スージェン・インコーポレーテッド 蛋白質キナーゼの調節剤３−メチリデニル−２−インドリノン
BR9916223A (pt) 1998-12-17 2001-09-04 Hoffmann La Roche 4-ariloxindóis como inibidores de cinases de proteìna jnk
GB9904933D0 (en) * 1999-03-04 1999-04-28 Glaxo Group Ltd Compounds
PT1255752E (pt) 2000-02-15 2007-10-17 Pharmacia & Upjohn Co Llc Inibidores de proteína quinases: 2-indolinonas substituídas com pirrolo
EP1294688A2 (fr) * 2000-06-02 2003-03-26 Sugen, Inc. Derives d'indolinone comme inhibiteurs de phosphatase/proteine kinase
US20030119839A1 (en) * 2001-12-13 2003-06-26 Nan-Horng Lin Protein kinase inhibitors
TW200301123A (en) * 2001-12-21 2003-07-01 Astrazeneca Uk Ltd New use
CA2506546A1 (fr) 2002-11-15 2004-06-17 Exelixis, Inc. Modulateurs de kinase

Also Published As

Publication number Publication date
EP1814545A4 (fr) 2009-06-10
BRPI0517968A (pt) 2008-10-21
MX2007005547A (es) 2007-07-05
NO20072887L (no) 2007-08-03
WO2006052936A2 (fr) 2006-05-18
JP2008519762A (ja) 2008-06-12
TW200631577A (en) 2006-09-16
RU2406725C2 (ru) 2010-12-20
US20080221192A1 (en) 2008-09-11
GT200500321A (es) 2006-09-04
KR20070084066A (ko) 2007-08-24
EP1814545A2 (fr) 2007-08-08
AU2005304719B2 (en) 2009-07-23
CA2583737A1 (fr) 2006-05-18
AR053652A1 (es) 2007-05-16
RU2007121505A (ru) 2008-12-20
WO2006052936A3 (fr) 2006-10-26
TNSN07176A1 (en) 2008-11-21
US8101608B2 (en) 2012-01-24
IL182687A0 (en) 2007-09-20
AU2005304719A1 (en) 2006-05-18
CA2583737C (fr) 2011-09-20
JP4917041B2 (ja) 2012-04-18

Similar Documents

Publication Publication Date Title
MA29216B1 (fr) Composes et compositions utilises comme inhibiteurs de la proteine kinase
MA28679B1 (fr) Composes et compositions utilises comme inhibiteurs de proteines kinases
MA30888B1 (fr) Compositions et procedes de modulation de recepteurs de c-kit et de facteur de croissance derive de plaquettes (pdgfr)
MA27997A1 (fr) Composes et compositions inhibiteurs de l'activite du recepteur tyrosine kinase
MA31153B1 (fr) Composés et méthodes pour moduler une kinase et indications associées
MA31704B1 (fr) Composés et compositions de 5-(4- (haloalkoxy) phényl) pyrimidine-2-amine utilisés comme inhibiteurs de kinases
TN2012000073A1 (fr) Derives des l-(piperidine-4-yl) pyrazole servant de modulateurs de gpr119
MX2008001969A (es) Compuestos y composiciones como inhibidores de proteina cinasa.
MA51673B1 (fr) Composés pour le traitement des troubles dépendants de kinases
FR21C1031I2 (fr) Derives de la n4-phenyl-quinazoline-4-amine et composes similaires en tant que inhibiteurs de la kinase tyrosine erbb type i pour le traitement de maladies hyperproliferatives
MA32705B1 (fr) Composes cycliques spiro-tetracycliques utiles en tant que modulateurs de la beta-secretase et leurs procedes d'utilisation
PL1940844T3 (pl) Związki i kompozycje jako inhibitory kinazy białkowej
MA30906B1 (fr) Composes et compositions en tant quinhibiteurs des proteines kinases
MA44795A (fr) Compositions de pyrrolopyrrole en tant qu'activateurs de la pyruvate kinase (pkr)
MA29772B1 (fr) Benzimidazoles substitues et procedes de preparation
MA31283B1 (fr) Produits dérivés de 2,3-dihydroimidazo[1,2-c]quinazoline substitués, utiles pour le traitement de troubles hyperlifératifs et de maladies associées à une angiogénèse
MA29377B1 (fr) Derives de la pyrimidine pour traitement de troubles a caractere hyperproliferatif
MXPA06014721A (es) Derivados de alquinilo como moduladores de los receptores de glutamato metabotropico.
MX2009008773A (es) Derivados de 3,4-dihidro-1,4-benzoxazina,3,4-dihidro-1,4-benzotiaz ina y 1,2,3,4-tetrahidro-quinoxalina como agonistas de adrenoreceptores alfa2c.
MA30772B1 (fr) Composes et compositions utilises en tant qu'inhibiteurs de proteine kinase
MA32134B1 (fr) Composés hétérocycliques
WO2008011476A3 (fr) Compositions et procédés destinés à moduler l'activité de la sirtuine
WO2006105516A3 (fr) Compositions et procedes pour le diagnostic et le traitement de troubles neuropsychiatriques
WO2006101783A8 (fr) Composes et compositions inhibiteurs des proteines kinases
MA29692B1 (fr) Derives de la xanthine en tant qu'agonistes selectifs du hm74a